While targeted disease-modifying therapies dominate the Castleman disease treatment market narrative, comprehensive supportive care and symptom management are essential components of optimal patient outcomes that address the multi-system manifestations of cytokine-driven disease. Anemia management represents a critical supportive care need, as bone marrow suppression from IL-6-driven hepcidin elevation and chronic inflammation affects over 60% of iMCD patients. Erythropoiesis-stimulating agents, intravenous iron supplementation, and red blood cell transfusions are frequently required, with successful IL-6 blockade often improving anemia as inflammatory blockade restores iron mobilization. Over 2,800 Castleman disease patients received anemia-directed supportive care interventions in 2025.

Fluid management and edema control are essential in TAFRO syndrome and other hyperinflammatory presentations, where capillary leak and hypoalbuminemia drive anasarca, pleural effusions, and ascites requiring diuretics, albumin replacement, and sometimes mechanical drainage. Castleman Disease Treatment Market data indicates that aggressive fluid management in acute presentations reduces organ dysfunction and improves survival, with nephrology consultation frequently required for renal dysfunction management. Thrombocytopenia in TAFRO and severe iMCD requires platelet transfusion support and careful monitoring for bleeding complications, with thrombopoietin receptor agonists being investigated for persistent cases.

Infection prophylaxis and management are critical given the immunosuppressive effects of both disease and treatment, with Pneumocystis jirovecii pneumonia prophylaxis recommended for patients on rituximab or high-dose corticosteroids, and antiviral prophylaxis for HHV-8 MCD patients. Growth factor support, nutritional optimization, and physical rehabilitation address the cachexia and functional decline associated with chronic cytokine exposure. Psychosocial support, including mental health services, patient navigation, and peer support through organizations like the CDCN, addresses the substantial psychological burden of rare disease diagnosis and chronic illness. The integration of supportive care into comprehensive treatment protocols, coordinated through multidisciplinary teams including hematology, nephrology, infectious disease, nutrition, and palliative care, is improving quality of life and enabling patients to tolerate definitive therapies. As supportive care protocols standardize and evidence accumulates for specific interventions, this aspect of Castleman disease management is transitioning from reactive symptom control to proactive, evidence-based care that optimizes patient outcomes alongside disease-targeted therapy.

Q1: What supportive care needs are common in Castleman disease? Anemia affects 60%+ of iMCD patients requiring erythropoietic support, while TAFRO syndrome requires aggressive fluid and edema management, thrombocytopenia support, infection prophylaxis, and nutritional optimization.

Q2: How does IL-6 blockade affect anemia in Castleman disease? Successful IL-6 blockade improves anemia by reducing hepcidin-driven iron sequestration and restoring iron mobilization, often reducing transfusion requirements as inflammatory blockade takes effect.

Q3: What multidisciplinary care is required for Castleman disease? Comprehensive care requires hematology, nephrology, infectious disease, nutrition, physical rehabilitation, and psychosocial support coordination to address multi-system cytokine-driven manifestations and treatment complications.